Charcot-Marie Tooth disease

Pharma News for Kyverna, Annovis, Astellas, FibroGen

Jun 13, 2023

FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result

charcot-marie-tooth-disease-market-cagr-trends-growth-size-share-forecast-therapies-therapy-therapeutics-treatment-drugs

Sep 03, 2021

Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies

Peloton Therapeutics

Feb 14, 2019

Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper